Compare CTNT & PRFX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CTNT | PRFX |
|---|---|---|
| Founded | 2016 | 2007 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5M | 3.1M |
| IPO Year | 2023 | 2020 |
| Metric | CTNT | PRFX |
|---|---|---|
| Price | $3.22 | $0.82 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 32.7M | 232.6K |
| Earning Date | 11-06-2026 | 09-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 57.74 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,288,536.00 | N/A |
| Revenue This Year | $78.50 | N/A |
| Revenue Next Year | $52.17 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 182.69 | N/A |
| 52 Week Low | $0.03 | $0.58 |
| 52 Week High | $2,120.00 | $5.39 |
| Indicator | CTNT | PRFX |
|---|---|---|
| Relative Strength Index (RSI) | 60.01 | 39.06 |
| Support Level | $2.95 | $0.58 |
| Resistance Level | $4.18 | $1.28 |
| Average True Range (ATR) | 0.34 | 0.04 |
| MACD | 0.19 | -0.01 |
| Stochastic Oscillator | 72.83 | 17.18 |
Cheetah Net Supply Chain Service Inc is a provider of logistics and warehousing services, historically in connection with the sale of parallel-import vehicles sourced in the U.S. to be sold in the PRC market, and more recently for the transportation of other goods between the U.S. and the PRC. Parallel-import vehicles in the PRC refer to automobiles purchased directly from overseas markets and imported for sale outside of the brand manufacturer's official distribution networks. The company operates as single report segment. The company operates in the USA and overseas.
PRF Technologies Ltd is a a diversified platform spanning speciality pharmaceuticals, drug-delivery technologies, and AI-driven renewable-energy analytics. PRF Technologies focuses on pharmaceutical therapies that emphasize reformulation and sustained-release drug-delivery technologies and AI-driven energy analytics. PRF-110, the company's lead product, is based on the local anesthetic ropivacaine and targets the postoperative pain relief market. The company has two operating segments composed of the Clinical Development segment, which facilitates the development of potential new drug compounds, and the Solar segment, which comprises the design and development of the company's intellectual property and the sale related service offerings.